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Abstract
Background: Spinocerebellar ataxia (SCA) is an uncommon form of progressive cerebellar ataxia with multiple genetic causes and marked variability in
phenotypic expression even across patients with identical genetic abnormalities. SCA27 is a recently identified SCA caused by mutations in the Fibroblast Growth
Factor 14 gene, with a phenotypic expression that is only beginning to be fully appreciated. We report here a case of a 70-year-old male who presented with slowly
worsening tremor and gait instability that began in his early adulthood along with additional features of parkinsonism on examination. Work-up revealed a novel
pathogenic mutation in the Fibroblast Growth Factor 14 gene, and symptoms improved with amantadine and levodopa. We also provide a review of the literature in
order to better characterize the phenotypic expression of this uncommon condition.
Methods: Case report and review of the literature.
Results: Review of the literature revealed a total of 32 previously reported clinical cases of SCA27. Including our case, we found that early-onset tremor (12.1¡
10.5 years) was present in 95.8%, while gait ataxia tended to present later in life (23.7¡ 16.7 years) and was accompanied by limb ataxia, dysarthria, and nystagmus.
Other features of SCA27 that may distinguish it from other SCAs include the potential for episodic ataxia, accompanying psychiatric symptoms, and cognitive impairment.
Discussion: Testing for SCA27 should be considered in individuals with ataxia who report tremor as an initial or early symptom, as well as those with additional findings
of episodic ataxia, neuropsychiatric symptoms, or parkinsonism.
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Introduction
Spinocerebellar ataxia (SCA) is a growing collection of autosomal
dominant cerebellar ataxias for which the underlying genetic etiologies
are being increasingly identified. To date, 44 SCA syndromes have
been described, with the first genetic cause for SCA1 reported in 1994
and the most recent genetic cause for SCA44 reported in 2017.1–3
As more causative genes are identified, marked variability in pheno-
typic expression has been noted across SCA syndromes and even
within patients with the same genetic abnormality.1,4 SCA27 was first
reported in 2006, but the spectrum of phenotypic expression is only
beginning to be elucidated.5–17 We present here a patient who was
found to have a novel, pathogenic mutation in the Fibroblast Growth
Factor 14 (FGF14) gene located at chromosome 13q33, the gene
associated with SCA27. We also provide a review of the literature in
order to better characterize the phenotypic expression of this uncom-
mon condition.
Case report
A 70-year-old male presented with worsening of a long-standing
tremor as well as imbalance and gait instability. The tremor began
roughly 50 years earlier in his 20s, was at first only noted in his right
arm, and progressively worsened over the years, becoming more
bothersome in the last couple of years. The tremor occurred at rest,
with posture holding, and action, and persisted throughout the day.
Freely available online
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services1
A mild tremor had developed in his left arm and head at some
uncertain time in the past. He had been tried on propranolol and
ropinirole for the tremor without benefit. The patient also reported
difficulty with balance and walking a straight line, dating back poten-
tially to elementary school. His balance and walking had been slowly
worsening since childhood to the point that he had been falling two or
three times a month for the last couple of years. He complained of
diplopia and visual symptoms that had been present since adolescence
and worsening for the last 7–8 years. Past medical history included
psychiatric diagnoses including post-traumatic stress disorder and
depression. He had completed vocational school after high school and
had no current complaints of cognitive difficulties. The patient does
not drink alcohol and therefore it is not known if the tremor is
responsive to alcohol. Family history was notable for a father and
paternal uncle with similar hand tremors, and a paternal aunt with a
reported diagnosis of Parkinson’s disease.
On examination, the patient had upbeating nystagmus with upward
gaze as well as a persistent horizontal nystagmus with lateral gaze.
He had mild symmetric rigidity in his bilateral upper extremities
that increased with contralateral motor activation, along with mild
bradykinesia and decrementing amplitudes with right-sided rapid
finger tapping. Bilateral rest, postural, and intention tremors were
observed in the bilateral upper extremities, right worse than left, along
with a high frequency, low amplitude persistent head tremor. There
was no tremor noted in the legs. Reflexes were normal and symmetric
in the bilateral upper and lower extremities. Sensation was intact to
light touch, vibration, and proprioception in the bilateral lower
extremities. He had mild dysmetria on finger-follow and finger-to-nose
testing bilaterally, as well as an ataxic, wide based gait.
Initial serological work-up was negative. Magnetic resonance imag-
ing (MRI) of the brain was normal and without any evidence of
cerebellar atrophy, findings suggestive of underlying multiple systems
atrophy, or other degenerative cerebellar disorder. Given the nystagmus
and progressive ataxia, genetic testing for SCAs was pursued and a
missense mutation in the FGF14 gene (c.326T.C; p.Phe109Ser) was
identified. This mutation had not been previously reported in a
database search of dbSNP or 1,000 Genomes, and was predicted to be
pathogenic, though verification of segregation of symptoms in his other
reported family members was not possible as they are deceased.
The patient was started on amantadine, which improved his head
tremor and led to marked improvement in falls with reduced gait
instability. Three months later, he was started on one tablet of carbidopa/
levodopa 25/100 mg three times a day, which further improved his hand
tremor (rest more than postural and action) and gait instability. At follow-
up 18 months from initial presentation, the patient has remained on the
same doses of medication and continues to report improvement in his
head tremor and balance. He does note that the tremor (rest, action, and
postural) has worsened over time, but he denies any motor fluctuations
related to the medications or dyskinesias and examination did not show
any progression of other signs of parkinsonism.
Methods
Written consent was obtained from our case patient and we also
subsequently performed a literature review to identify all manuscripts
that provided clinical information on patients with a diagnosis of
SCA27 due to genetic alterations of the FGF14 gene. We performed
the search using PubMed in October 2017 including all dates of
publication with the search terms of FGF14, Fibroblast Growth Factor
14, SCA27, Spinocerebellar Ataxia 27, and FGF14 AND Spinocerebellar
Ataxia. A total of 226 papers were identified of which only 13 papers were
found to contain positive patient information related to the diagnosis of
SCA27 after exclusion of duplications. Details can be found in Table 1.
From these papers, a total of 38 individuals were identified by genetic
testing, clinical examination, or family report of similar symptoms to
gene-positive relatives.5–17 Of the 38 patients reported, seven either did
not have genetic confirmation of SCA27 or lacked any clinical exami-
nation information. One of these patients, however, was the father of
two genetically confirmed, non-identical sons. Given the high likelihood
Table 1. Results of Search for Articles from PubMed Using Various Key Words and their Combinations
Key Words and Combinations Number of Publications
Total Included Excluded
FGF14 73 11 62 (not relevant)
Fibroblast Growth Factor 14 99 10 89 (not relevant)
SCA27 19 6 13 (not relevant)
Spinocerebellar ataxia 27 9 6 3 (not relevant)
FGF14 AND spinocerebellar ataxia 26 11 15 (not relevant)
Total number of articles identified from key word searches 226
Total number of additional articles included from the reference sections of the shortlisted articles 0
Final number of articles included for review after removing the duplicates 13
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of the patient also having a gene mutation, his clinical data were included.
Ultimately, six patients were excluded. Table 2 summarizes the demo-
graphic and clinical findings for the resulting 33 patients, including our
case report, in which clinical and/or genetic data were usable.
Discussion
SCA27 is a slowly progressive, autosomal dominant cerebellar
ataxia caused by a mutation in the FGF14 gene. The 14 initially
reported patients, who are commonly referred to as the Dutch cohort,
presented with a slowly progressive ataxia with postural tremor, and
sometimes associated head titubation, as the initial manifestations.5,6
In addition, these patients frequently had associated nystagmus,
dysarthria, ambulation difficulties, limb ataxia, orofacial dyskinesias,
psychiatric symptoms (depression and aggressive outbursts), and cogni-
tive delay. However, since this initial description, an additional 19
patients, including our case, have been reported leading to expansion
of the phenotype to include episodic ataxia and parkinsonism.5–17
With the increased clinical information from the descriptions of
33 patients with SCA27 reported to date, we are better able to char-
acterize the frequency of symptoms associated with this SCA and
potentially improve our understanding of these symptoms.
Based on a recent review of the clinical features of 30 different
autosomal dominant SCAs, SCA27 shares several cardinal features
with these SCAs including ataxic gait (89.7% vs. 97%), nystagmus
(84% vs. 56%), dysarthria (91.3% vs. 90%), and limb ataxia (81.8% vs.
94%).4–16 Tremor was found to be present in a much higher
percentage of SCA27 patients (95.8%) than observed on average
among other SCAs (40%).4–8,11–16 The percentage of those SCA27
patients with tremor was also higher than the other SCAs most
commonly associated with tremor including SCA2 (49.8%) and
SCA12 (70%).4 Tremor was also the initial presenting symptom in
57.7% of SCA27 patients compared with an average of 4% seen
among other SCAs.4–17 Initial symptom onset occurs earlier in life in
SCA27 than other SCAs (12 ¡ 10 years vs. 35 ¡ 11 years), yet it
appears to have a slower progression than other SCAs with only 13.8%
of patients reporting severe gait impairment and only 17.4% reporting
severe dysarthria despite having symptoms for several decades.1,4–17
This finding is frequently seen among the non-polyglutamine expan-
sion SCAs, even when only comparatively followed for a few years.17,18
Finally, 20% (four out of 20) of the SCA27 patients with MRI infor-
mation were reported to have abnormal MRI with evidence of cere-
bellar atrophy.5–16 Comparatively, during the disease course of other
SCAs, cerebellar hemisphere or vermian atrophy is frequently reported
in addition to more disease-specific findings of brainstem, pontine, basal
ganglia, or cortical atrophy.1,19
Like other reported types of SCAs, SCA27 has been associated with
the occurrence of non-ataxia symptoms. For example, psychiatric
symptoms including depression and aggressive outbursts were reported
in 56% of patients.5–17 This suggests a higher incidence rate than
reported in other SCAs with the exception of SCA2, SCA17, and
dentatorubro-pallidoluysian atrophy, which have occurrence rates as
high as 87%, 63%, and 65%, respectively.4 Cognitive impairment may
also be a more prominent feature in SCA27 as it has been reported in
50% of patients, whereas across other autosomal dominant SCAs it has
only been reported in about 20% of patients.4–17
Episodic ataxia, reported in 21.2% of SCA27 patients, is another
feature that is uncommon among most SCAs.5–17,20,21 SCA6, which is
caused by mutations in the CACNA1A gene, is the only other SCA
infrequently associated with an episodic ataxia, though mutations in
this gene also cause episodic ataxia 2.20,22 The FGF14 gene, like the
genes linked to SCA6 and the autosomal dominant episodic ataxia
disorders, has been associated with ion channels and excitatory
neurotransmission, potentially explaining the development of episodic
ataxia in some of these patients.20,22–26
The addition of our patient case presented here potentially expands
the phenotypic expression of SCA27 to include a dopamine-responsive
parkinsonism (bradykinesia, rigidity, and rest tremor). FGF14 is traf-
ficked to and expressed in axons of the striatopallidal and striatonigral
pathways, and FGF14 knockout mice have been shown to have an
inappropriate response to dopaminergic stimulation27 that could pote-
ntially contribute to the development of parkinsonism in some SCA27
patients. Limited information could be gleaned from our literature
search about the presence of parkinsonian features in prior SCA27
reports. Several of the patients from the Dutch cohort were trialed
on a ‘‘dopaminergic medication’’ with no reported improvement in
tremor.5,6 One subject in the Dutch cohort even underwent dopamine
imaging as part of his work-up with the findings reported to be not
consistent with a diagnosis of Parkinson’s disease.5,6 Dyskinesias have
also been reported in 10 prior cases of SCA27, but details are lacking
to determine what these movements represent and if there was any
relation to dopaminergic therapy or not.5,6 Overall, our case in
combination with prior SCA27 reports support that some patients may
manifest parkinsonian symptoms.
Our patient also showed improvement in head tremor and gait
stability when started on amantadine. Amantadine slows the inactiva-
tion of sodium channels and thus may allow for increased excitation,
helping to reverse the decreased cell firing of Purkinje and granule cells
after depolarization that is associated with the genetic defect in
FGF14.28–30 Although amantadine has previously been shown to
potentially help improve cerebellar ataxia, Friedreich’s ataxia, and
parkinsonism,31,32 there are no reports to date of amantadine or any
other medication found to successfully reduce tremor and/or gait
stability in SCA27.5–17 Thus, research is needed to better determine if
amantadine or levodopa may be reasonable treatment options to
consider for SCA27.
There are some limitations to this review including the overall small
number of SCA27 cases reported to date and the inconsistent report-
ing of clinical features, particularly related to parkinsonism, cognition,
and particularly mood with the initial Dutch cohort entailing the
majority of patients with neuropsychiatric complaints. Additionally,
apart from the initially identified mutation in the FGF14 gene (F145S),
the pathogenicity of each reported genetic alteration has not been
verified with in vitro or animal model testing to prove causality and
thus remains an area in need of further research. While SCA27 may be
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a rare disease, it is also possible that the diagnosis is being missed or
that patients are being incorrectly diagnosed with essential tremor (ET)
due to the early onset of tremor, its slow progression, and the attri-
bution of gait ataxia to the ‘‘cerebellar signs’’ of ET.33 In our patient
case, it is possible some of the motor symptoms are due to concur-
rent Parkinson’s disease and SCA27. We do not have dopaminergic
imaging, though the utility of such imaging in SCA27 is questionable
given that several SCAs with associated parkinsonism, including SCA2,
SCA3, and SCA17, can have abnormal dopaminergic imaging.34–37
Therefore, such imaging is unlikely to be able to confirm the diagnosis
of Parkinson’s disease. Our patient also has not shown progression of
his parkinsonism over the last 18 months, which helps support that his
findings are not related to underlying Parkinson’s disease. However,
post-mortem examination would provide the best clarification as to
whether pathology that represents typical Parkinson’s disease exists or not.
In summary, this study provides a synopsis of the clinical char-
acteristics of SCA27 based on gene-confirmed cases reported to date.
Our findings support that tremor is an early and prominent feature in
SCA27, and that the disorder may be associated with episodic ataxias
as well as non-ataxia features including psychiatric symptoms and cogni-
tive impairment. We also report parkinsonism as a potential feature of
SCA27, though further follow-up and research will be needed to fully
determine its possible association. Marked overlap in the phenotypic
expression of the multiple SCAs can lead to difficulties with predicting
which SCA the patient is likely to have prior to genetic testing.1
Therefore, consideration for SCA27 should be high for individuals
with ataxia and tremor as initial, or early, symptoms as well as those
with psychiatric symptoms, cognitive delay, parkinsonism, or episodic
ataxia. Finally, if SCA27 is diagnosed, a trial of amantadine could be
considered.
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